Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, International, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Clinical Worsening Study of UT-15C in Subjects With Pulmonary Arterial Hypertension Receiving Background Oral Monotherapy

NCT01560624 is registered in ClinicalTrials.gov with United Therapeutics as lead sponsor.

NCT NCT01560624
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01560624 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, International, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Clinical Worsening Study of UT-15C in Subjects With Pulmonary Arterial Hypertension Receiving Background Oral Monotherapy
Lead sponsor
United Therapeutics
Phase
Phase 3
Overall status
Completed
Start date
June 26, 2012
Completion date
June 24, 2018
Enrollment
690 (actual)
Sites
155

Conditions

As the registry lists them; a condition with its own page is linked.

pulmonary arterial hypertension